The University of Chicago Header Logo

Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease.

Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease. Inflamm Bowel Dis. 2023 Dec 22.

View in: PubMed